(0.24%) 5 144.00 points
(0.16%) 38 501 points
(0.36%) 17 911 points
(-0.49%) $83.44
(0.57%) $1.934
(0.05%) $2 348.30
(0.27%) $27.61
(2.41%) $944.30
(-0.21%) $0.933
(-0.27%) $10.99
(-0.38%) $0.797
(1.26%) $93.03
Live Chart Being Loaded With Signals
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs...
Stats | |
---|---|
本日の出来高 | 1.10M |
平均出来高 | 1.66M |
時価総額 | 1 550.87B |
EPS | ¥0 ( 2024-02-08 ) |
次の収益日 | ( ¥25.37 ) 2024-05-08 |
Last Dividend | ¥2.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 34.60 |
ATR14 | ¥1.939 (0.08%) |
ボリューム 相関
Sysmex Corporation 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Sysmex Corporation 相関 - 通貨/商品
Sysmex Corporation 財務諸表
Annual | 2022 |
収益: | ¥410.50B |
総利益: | ¥216.08B (52.64 %) |
EPS: | ¥72.94 |
FY | 2022 |
収益: | ¥410.50B |
総利益: | ¥216.08B (52.64 %) |
EPS: | ¥72.94 |
FY | 2022 |
収益: | ¥363.78B |
総利益: | ¥190.59B (52.39 %) |
EPS: | ¥210.88 |
FY | 2021 |
収益: | ¥305.07B |
総利益: | ¥154.30B (50.58 %) |
EPS: | ¥158.65 |
Financial Reports:
No articles found.
Sysmex Corporation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥40.00 (N/A) |
¥0 (N/A) |
¥2.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.500 | 2001-03-27 |
Last Dividend | ¥2.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 46 | -- |
Total Paid Out | ¥628.25 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.35 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.53 | |
Div. Directional Score | 9.65 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8570.T | Ex Dividend Knight | 2023-08-30 | Semi-Annually | 0 | 0.00% | |
7905.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7059.T | Ex Dividend Junior | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6370.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5288.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4346.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
3513.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2742.T | Ex Dividend Knight | 2024-02-28 | Semi-Annually | 0 | 0.00% | |
9632.T | Ex Dividend Knight | 2024-01-30 | Semi-Annually | 0 | 0.00% | |
8168.T | Ex Dividend Junior | 2024-02-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.103 | 1.500 | 7.94 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0794 | 1.200 | 7.35 | 8.82 | [0 - 0.3] |
returnOnEquityTTM | 0.112 | 1.500 | 9.87 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.390 | -1.000 | 6.10 | -6.10 | [0 - 1] |
currentRatioTTM | 3.10 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 1.972 | 0.800 | 3.11 | 2.49 | [0.8 - 2.5] |
cashRatioTTM | 0.603 | 1.500 | 7.76 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0882 | -1.500 | 8.53 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 37.92 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 108.38 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 28.58 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.123 | -1.500 | 9.51 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.532 | 1.000 | 4.47 | 4.47 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.168 | 1.000 | 8.65 | 8.65 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 1.355 | 1.000 | 3.58 | 3.58 | [0.2 - 2] |
assetTurnoverTTM | 0.773 | 0.800 | 8.18 | 6.55 | [0.5 - 2] |
Total Score | 12.77 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.55 | 1.000 | 6.61 | 0 | [1 - 100] |
returnOnEquityTTM | 0.112 | 2.50 | 9.92 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 28.58 | 2.00 | 0.474 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.25 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 108.38 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.390 | 1.500 | 6.10 | -6.10 | [0 - 1] |
pegRatioTTM | 0.907 | 1.500 | 7.28 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.155 | 1.000 | 8.63 | 0 | [0.1 - 0.5] |
Total Score | 6.53 |
Sysmex Corporation
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. The company offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. It also provides urine formed sediment analysis systems; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, the company offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; cancer genome profiling systems; and cytogenic testing and lab assay services. It is also involved in the development and sale of software for diagnostic information systems; provision of facility management, office, and welfare services; development, manufacture, and sale of nucleic acid analogs; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. Sysmex Corporation has a strategic alliance with QIAGEN N.V. for the development and commercialization of cancer companion diagnostics using Plasma-Safe-SeqS technology. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。